Biodexa unveils "serenta" as the name of its upcoming phase 3 study in familial adenomatous polyposis (fap)

June 23, 2025 biodexa unveils "serenta" as the name of its upcoming phase 3 study in familial adenomatous polyposis (fap) biodexa pharmaceuticals plc (“biodexa” or “the company”), (nasdaq: bdrx), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is pleased to announce it has selected serenta as the brand name for its upcoming phase 3 clinical study in familial adenomatous polyposis (fap). in conjunction with this announcement, the company launched a dedicated website, www.serentatrial.com, to provide information and resources for patients, caregivers, and healthcare professionals.
BDRX Ratings Summary
BDRX Quant Ranking